Anticoagulation: Risks and benefits in atrial fibrillation

Geriatrics

Volumn 51, Issue 6, 1996, Pages 22-31

  Fiore, Louis D ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOGLUTETHIMIDE; AMIODARONE; ANDROGEN; ANTICOAGULANT AGENT; ANTITHYROID AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CHLORAL HYDRATE; CIMETIDINE; CLOFIBRATE; COLESTYRAMINE; COTRIMOXAZOLE; DEXTROPROPOXYPHENE; DISULFIRAM; ERYTHROMYCIN; GLUCAGON; GLUTETHIMIDE; GRISEOFULVIN; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE; RIFAMPICIN; SALICYLIC ACID DERIVATIVE; SULFINPYRAZONE; TAMOXIFEN; THYROID HORMONE; UNINDEXED DRUG; WARFARIN;

AGE; ANTICOAGULATION; BLEEDING; DIABETES MELLITUS; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; PATIENT SELECTION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGE FACTORS; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; EMBOLISM; HEART; HUMANS; MIDDLE AGED; RISK FACTORS; WARFARIN;

EID: 0030324768     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. Arch Intern Med 1987; 147:1561-4.
2. Ezekowitz MD, Bridgers SL, James KE, et al, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992; 327:1406-12.
3. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991; 84:527-39.
4. Petersen P, Boysen G, Godtfredsen J, Anderson ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1989; 1:175-9.
5. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323:1505-11.
6. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18:349-55.
7. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154:1449-57.
8. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1,010 treatment years in 551 outpatients. J Intern Med 1991; 229:351-5.
9. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897-902.
10. Levins MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest 1992; 102:352S-63S.
11. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156:409-16.
12. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemology, prediction, and prevention. Am J Med 1993; 95:315-28.
13. Landefeld CS, Rosenblatt MW. Bleed-ing in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87:153-9.
14. McInes GT, Helenglass G. The performance of clinics for outpatient control of anticoagulation. J R Coll Physicians Land 1987; 21:42-5.
15. Gurwitz JH, Goldberg RJ, Holden A, Knapic N, Ansell J. Age-related risks of long term oral anticoagulant therapy. Arch Intern Med 1988; 148:1733-6.
16. Forfar JC. A 7-year analysis of hemorrhage in patients in long-term anticoagulant treatment. Br Heart J 1979; 42:128-32.
17. Cheng HJ, Bell JR, Deroo DB, Kirk JW, Wasson JA. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med 1990; 150:83-7.
18. Kutner M, Nixon G, Silverstone F. Physicians' attitudes toward oral anticoagu-lants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991; 151:1950-3.
19. McCrory DC, Matchar DB, Samsa G, Snaders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995; 155:277-81.
20. Rubin P. Editorial comment. Lancet 1988; 297:1260.
21. O'Connell JE. Warfarin in chronic atrial fibrillation in the elderly [letter]. Lancet 1993; 342:48.
22. Fihn SD, McDonell M, Martin D, et al, for the Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation. Ann Intern Med 1993; 118:511-20.
23. Lundstrom T, Ryden L. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med 1989; 225:137-42.
24. Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Management of anticoagulation in outpatients. Experience with an anticoagulation service in a municipal hospital setting. Arch Intern Med 1977; 137:197-202.
25. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: Experience with an anticoagulation clinic. Arch Intern Med 1984; 144:1966-8.
26. Petty GW, Lennihan L, Mohr JP, et al. Complications of long-term anticoagulation. Ann Neurol 1988; 23:570-3.
27. Sixty Plus Reinfarction Study Research Group. Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1982; 1:64-8.
28. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy: An analysis of risk factors. Arch Intern Med 1993; 153:1557-62.
29. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol 1989; 42:759-64.
30. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87:144-52.
31. Scott PJ. Anticoagulant drugs in the elderly: The risks usually outweigh the benefits. Br Med J 1988; 297:1261,1263.
32. Hirsh J, Dalen JF, Deykin D, Poller L. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal theraputic range. Chest 1992; 102:312S-26S.
33. Hart RG, Halperin JL. Atrial fibrillation and stroke: Revisiting the dilemmas. Stroke 1994; 25:1337-41.
34. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-91.
35. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116:901-4.
36. James AH, Britt RP, Rankino CL, Thompson SG. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45:704-6.
37. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121:676-83.